February 27, 2019 / 12:43 PM / in 20 days

Sarepta to buy gene therapy developer Myonexus for $165 mln

Feb 27 (Reuters) - Sarepta Therapeutics Inc said on Wednesday it exercised its option to buy privately held gene therapy maker Myonexus Therapeutics Inc for $165 million.

Sarepta and Myonexus had entered into an exclusive partnership last May to develop Myonexus’ five gene therapy candidates for treating different forms of Limb-girdle muscular dystrophy, a group of muscle-wasting disorders.

As part of the deal, Sarepta had an exclusive option to acquire Myonexus. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shailesh Kuber)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below